US regulatory issues unlikely to derail Fresenius-Akorn deal
The proposed pharmaceutical merger between Fresenius Kabi and Akorn is unlikely to be halted by US regulatory issues, MLex has learned.The proposed pharmaceutical merger between Fresenius Kabi and Akorn is unlikely...To view the full article, register now.
Already a subscriber? Click here to view full article